Pulmonary Procedures |

Rigid Bronchoscopic Intervention for Patients With Untreated Small Cell Lung Cancer FREE TO VIEW

Masahide Oki, MD; Hideo Saka, MD; Yoshihito Kogure, MD; Masashi Nakahata, MD; Saori Oka, MD; Rie Tsuboi, MD; Kazumi Hori, MD; Yasushi Murakami, MD; Yuko Ise, MD; Chiyoe Kitagawa, MD
Author and Funding Information

Nagoya Medical Center, Nagoya, Japan

Chest. 2015;148(4_MeetingAbstracts):848A. doi:10.1378/chest.2268090
Text Size: A A A
Published online


SESSION TITLE: Rigid Bronchoscopy

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: Small cell lung cancer (SCLC) has the most aggressive nature of any type of lung cancer, and often causes airway stenosis leading to a life-threatening condition. Rigid bronchoscopic intervention has been reported to be useful as a bridge to tumor-specific therapy as well as palliative therapy for patients with malignant airway stenosis, but its role for SCLC patients is unclear. The aim of this study was to investigate the efficacy of rigid bronchoscopic intervention for patients with airway stenosis caused by SCLC.

METHODS: Patients with airway stenosis due to untreated SCLC who underwent rigid bronchoscopic treatment under general anesthesia from August 2006 to September 2014 in a single center were retrospectively reviewed.

RESULTS: In 459 patients who underwent rigid bronchoscopy during the study period, 12 chemoradiotherapy naïve SCLC patients (6 male, 6 female; median 73.5 years; range, 55-80 years) with airway stenosis were eligible for analysis. Six patients (50%) had stage IIIB and six (50%) had stage IV disease. Ten patients (83%) had ECOG-performance status 3 or 4. All patients underwent stent placement (silicone stenting in 10, metallic stenting in 2). Eight out of 11 patients (73%) with supplemental oxygen before intervention could be freed from the use of supplemental oxygen after intervention. Nine patients (75%) received tumor-specific therapy (chemotherapy in 8, radiation therapy in 1) after the procedure. Median survival after the procedure at the time of data collection was 47.5 days (range, 5-617 days; 119 days in patients with postprocedural tumor-specific therapy, 15 days in patients without postprocedural tumor-specific therapy).

CONCLUSIONS: The prognosis was poor in this study population with advanced SCLC with poor performance status who required immediate intervention. Although rigid bronchoscopic intervention was not always beneficial, it remains a valuable option as a bridge therapy and a palliative therapy.

CLINICAL IMPLICATIONS: Despite poor prognoses in some patients, rigid bronchoscopic intervention is a valuable option for SCLC patients with airway stenosis.

DISCLOSURE: The following authors have nothing to disclose: Masahide Oki, Hideo Saka, Yoshihito Kogure, Masashi Nakahata, Saori Oka, Rie Tsuboi, Kazumi Hori, Yasushi Murakami, Yuko Ise, Chiyoe Kitagawa

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543